Skip to main content

Featured

5 Things to Know Today (Oct. 1): Minimum Wage Hike, Cooler U.S. Inflation, Oil Below $100

  Thursday October 1, 2026 A new quarter, a higher minimum wage in Ontario and a softer inflation read south of the border. Here are the five things that matter to your wallet today. 1 Ontario's minimum wage rises to $17.95 today Ontario's general minimum wage climbs 35 cents, from $17.60 to $17.95 an hour, as of October 1 — a roughly 2% bump tied to Ontario's CPI. The student rate goes to $16.90 (from $16.60) and the homeworker rate to $19.70. A full-time worker at 40 hours a week earns about $718 a week before deductions. Federally regulated workers already have an $18.15 floor, which has applied since April 1. What it means for you: If you pay anyone by the hour — a cleaner, a part-time helper, a seasonal worker — hours worked from today forward must be paid at no less than $17.95, even if the pay period started in September. Workers should check their next paycheque. 2 Cooler U.S. inflation eases the pressure on rate hikes The Fed's preferred inflation gauge came i...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment